The potential interaction between Signifor and alcohol has not been thoroughly investigated. Increases in liver enzymes, suggesting liver damage, have been reported in some patients taking Signifor, however. Because excessive alcohol consumption also can damage the liver, patients should discuss with their healthcare provider if it’s safe to drink while on the medication.
In the PASPORT-CUSHINGS trial that supported Signifor’s approval, reductions in urinary cortisol levels and Cushing’s signs and symptoms were observed as early as one month after starting treatment. Normalized urinary cortisol levels were observed as early as three months. Because each person is unique and can respond differently to a medication, patients are advised to talk with their healthcare team about how the therapy can help in their particular case.
The most commonly reported side effects of Signifor include diarrhea, nausea, high blood sugar, gallstones, headache, abdominal pain, fatigue, and diabetes. If patients have new or worsening side effects, they should discuss the issue with their doctor, who may recommend reducing their dosage.
Weight gain hasn’t been reported as a side effect of Signifor, but it’s a known symptom of Cushing’s disease. Clinical trial data suggest the therapy is associated with weight loss. Patients should talk with their healthcare team if they experience weight gain or any other unanticipated effects of treatment.